Bristol Myers Squibb Company’s Sotyku and Mallinckrodt plc’s Terlivez provided two different kinds of examples that the late summer doldrums that had afflicted the novel approvals at the US FDA are decidedly over.
BMS sees oral Sotyktu as a blockbuster in waiting, with strong labeling in hand for the large plaque psoriasis market after a single review cycle